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1  |  INTRODUC TION
Gynaecomastia is defined as a benign glandular proliferation in 
the male breast and has to be differentiated from lipomastia (a 
proliferation of adipose rather than glandular tissue), which is com-
monly seen in obese males.1 The two forms can be differentiated 
by palpation but more accurately by ultrasound.2 We have previ-
ously demonstrated that an imbalance between testosterone and 
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Abstract
Objective: Gynaecomastia is frequent in pubertal boys and is regarded as a self-lim-
iting abnormality. However, longitudinal studies proving this hypothesis are scarce.
Design: Longitudinal follow-up study (median 2.4, range 1.0-4.8 years).
Methods: The regression of breast diameter was analysed in 31 pubertal boys aged 
11.7-16.1 (median 13.2) years with gynaecomastia. Furthermore, weight changes (as 
BMI-SDS) and pubertal stage, oestradiol [E2], oestriol, oestrone, androstenedione, 
testosterone [T], dihydrotestosterone, gonadotropins, IGF-1, and IGFBP-3 serum con-
centrations determined at first clinical presentation were related to breast diameter 
regression determined by palpation and disappearance of breast glandular tissue in 
ultrasound in follow-up to identify possible predictors of breast regression.
Results: During the observation period, the breast diameter decreased (in median −1 
(interquartile range [IQR] −5 to +1) cm). At follow-up, 6% of boys had no breast en-
largement any more, and 65% developed lipomastia. Gynaecomastia was still present 
in 29%. None of the analysed hormones was related significantly to breast diameter 
regression or disappearance of breast glandular tissue. In multiple linear regression 
analyses adjusted for observational period, as well as age and BMI-SDS at first pres-
entation, changes in BMI-SDS (β-coefficient 6.0 ± 2.3, p = .015) but not the E2/T 
ratio or any other hormone determined at baseline was related to changes in breast 
diameter.
Conclusions: Breast diameter regression seems not to be predictable by a hormone 
profile in pubertal boys with gynaecomastia. In pubertal boys presenting with gynae-
comastia, conversion to lipomastia of smaller volume is common. The reduction of 
weight status was the best predictor of breast diameter regression.
K E Y W O R D S
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oestradiol concentrations is the most striking finding in pubertal boys 
with gynaecomastia compared to pubertal boys with lipomastia.3
Physiological gynaecomastia in pubertal boys is regarded as a 
self-limiting condition.1,4-10 However, longitudinal data are scarce 
and only three studies have analysed boys with gynaecomastia lon-
gitudinally.7,8,10 Importantly, it is unclear, which factors predict a 
regression of gynaecomastia. Such predictors would be helpful to 
advise the affected patients for example if surgery of gynaecomas-
tia is requested. It is well known that pubertal gynaecomastia has a 
negative impact on the self-esteem of adolescent boys. It can lead 
to depression as well as decreased participation in various social 
activities.11
The aim of this longitudinal study was to identify predictors of 
breast diameter regression in pubertal boys with gynaecomastia 
based on the diagnostic work-up at first presentation in our clinic 
consisting of ultrasound of breast, gonadotropins, IGF-1, IGFBP-3, 
and a comprehensive serum profile of sex steroid hormones and 
their precursors,3 using a liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) steroid profiling method.12
2  |  METHODS
The study was approved by the local ethics committee of the 
Vestische Kinder- und Jugendklinik, University of Witten/Herdecke 
in Germany. Written informed consent was obtained from all boys 
and parents of the participants.
All pubertal boys presenting with gynaecomastia at the Vestische 
Kinder- und Jugendklinik Datteln, University of Witten Herdecke 
in the time period between 1.10.2013 and 2.5.2019 and recruited 
for our previous study 3 were contacted for this follow-up exam-
ination. This cohort consisted of 86 boys with gynaecomastia. All 
boys who agreed to participate and with a follow-up interval of at 
least one year after baseline and having achieved a voice break (as 
indirect parameter for achieving the end of puberty) were included 
in this study. Boys with surgery of their breast were excluded from 
this study. Boys with pseudogynaecomastia (including lipomas-
tia) at baseline or gynaecomastia due to syndromes (eg Klinefelter 
syndromes) or disorders of sexual development or taking any med-
ication were also excluded from the study. For details of the initial 
study recruitment see.3
2.1  |  Measurements
We analysed height, weight and breast diameter determined by pal-
pation on each side at baseline and follow-up examination. Breast 
diameter was measured by a flexible measuring tape to the nearest 
cm. Furthermore, an ultrasound examination of the breast was per-
formed at baseline and follow-up.
Height was measured to the nearest millimetre using a wall-
mounted stadiometer. Weight was measured in underwear to the 
nearest 0.1 kg using a calibrated balance scale. BMI was calculated 
as weight in kilograms (kg) divided by the square of height in me-
ters (m2). The degree of overweight was quantified using Cole's least 
mean square method, which normalized the BMI skewed distribu-
tion and expressed BMI as a standard deviation score (BMI-SDS).13 
Reference data for German boys were used.14
Ultrasound measurements were performed by one well-trained 
investigator using a transportable Siemens Logic E ultrasound sys-
tem with a 12 MHz linear transducer. Adipose tissue is character-
ized in the ultrasound as hypoechoic or anechoic, while ultrasound 
signs of breast tissues are retroareolar ovoid hyperechoic tissue and 
branched duct development flame-shaped with finger-like exten-
sions into the surrounding tissue presenting as central hypoechoic 
star-shaped areas encircled by hyperechoic peripheral rim.2,15-17 If 
F I G U R E  1  Ultrasound of the breast in a 11.8-year-old boys with gynaecomastia (breast diameter 10 cm on each side, height 149.0 cm, 
weight 46,0 kg, BMI-SDS 0.90) at baseline (A) and lipomastia (B) at follow-up 3.7 years later (breast diameter 4 cm on each side, height 
173.5 cm, weight 67.0 kg, BMI-SDS 0.74) [Colour figure can be viewed at wileyonlinelibrary.com]
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any sign of breast tissue was detected by ultrasound the boy was 
classified as having gynaecomastia even if there were also hints of 
adipose tissue. An example of gynaecomastia in ultrasound which 
converted to lipomastia in the follow-up examination is presented 
in Figure 1.
Available data from the first presentation at our clinic were 
pubertal stage (Tanner stage P as well as testis volumes), height, 
weight, breast diameter on each side, serum gonadotropins (LH, 
FSH), IGF-1, IGFBP-3, and serum sex steroid hormones (oestradiol 
[E2], oestriol [E3], oestrone [E1], androstenedione [A], testosterone 
[T], dihydrotestosterone [DHT]) determined by liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS, for details see3). In 
order to interpret the relationship between E2 and T we calculate 
the E2 to T ratio.
2.2  |  Statistics
Statistical analyses were performed using the Winstat® software 
package (R. Fitch Software, Bad Krozingen, Germany). For descrip-
tive analysis, data were presented as median, interquartile range 
(IQR) and range.
To compare baseline variables, Fisher exact test, Student's t-test 
for unpaired observations, and Mann-Whitney U-test were used as 
appropriate. Normal distribution was tested by the Kolmogorov-
Smirnov test. Associations were calculated by Spearman rank 
correlation.
Changes during the observation period were calculated as value 
at follow-up minus baseline value. To statistically assess these 
changes, Fisher exact test, Student's t-test for paired observations, 
and Wilcoxon test were used as appropriate.
We performed a multiple linear backwards regression analysis 
with the dependent variable ‘change of breast diameter’ (sum of the 
changes of left and right breast diameter in cm) and the independent 
variables observation period, age at baseline, BMI-SDS and E2/T 
ratio at first presentation as well as all baseline hormone values re-
lated to breast diameter regression in univariate analyses with a p-
value <.10.
A p-value p < .05 was considered as significant in the multiple 
linear regression analysis. In univariate tests and Spearman rank cor-
relations, a p-value <.005 was assigned as significant to account for 
multiple comparisons.
3  |  RESULTS
One boy with gynaecomastia received surgery of the breasts and 
was excluded from this longitudinal analysis. A total of 31 boys with 
gynaecomastia agreed to participate in this longitudinal study and 
were included in the analyses (baseline characteristics see Table 1). 
They were re-examined 2.4 (median, IQR 1.3-2.9, range 1.0-4.8) 
years after the first presentation. These 31 boys did not differ sig-
nificantly from the 55 boys with gynaecomastia not included in this 
longitudinal study in respect to diameter of breast enlargement, age, 
testis volume, Tanner stage, gonadotropins, sex steroid hormones, 
and gonadotropins concentrations at baseline. The reasons for lack 
of follow-up were missing contact (n = 18) or refusal of re- presenta-
tion for follow-up (n = 37).
During follow-up, the weight status did not change significantly 
(ΔBMI-SDS in median + 0.20 (IQR −0.30–0.41, range −1.76–1.46, 
p = .367). At re-evaluation, most boys converted to lipomastia (see 
Figure 2).
The two boys with complete remission of their gynaecomastia 
had a breast enlargement of 8 respective 7 cm on each side at base-
line. One of these boys reduced his BMI-SDS (−1.45), the other boy 
had stable BMI-SDS in the observation period (−0.02).
At baseline, eight (88.9%) of the nine boys with remaining gynaeco-
mastia in the follow-up had a breast enlargement >4 cm on each side. 
At follow-up, six (66.6%) of these boys had a breast enlargement >4 cm 
on each side. At baseline, the breast diameters were 8 (median, IQR 
4–11, range 3–21) cm on the left size and 8 (median, IQR 4–12, range 
0–21) cm on the right size. At follow-up, the breast diameters were 9 
TA B L E  1  Baseline characteristics of the study cohort
Number 31
Age [years] 13.2 (11.8–14.2) [11.7–16.1]
BMI-SDS 0.69 (0.18–1.76) [−1.15–2.96]
Breast diameter left [cm] 8 (4–11) [3–28]
Breast diameter right [cm] 8 (3–11) [0–28]
Testis volume right [ml] 6 (5–11) [4–20]
Testis volume left [ml] 6 (5–11) [4–20]
Tanner stage P 3 (2–4) [1–5]
Duration of breast swelling 
[months]
12 (6–24) [2–36]
Note: Data as median, interquartile range in () and range in []
F I G U R E  2  Findings at 2.4-year follow-up in 31 pubertal boys 
with gynaecomastia at initial presentation
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(median, IQR 4–16, range 4–22) cm on the left side and 10 (median, 
IQR 3–16, range 0–22) cm on the right side. The changes of the breast 
diameter were on the left side −1 (median, IQR −1–5, range −2–10) cm 
and on the right side −1 (median, IQR −1-5, range −2-5) cm. The boys 
with persistent gynaecomastia had a slight increase of their BMI-SDS 
during follow-up (median + 0.09, IQR −0.41–0.46, range −1.76–0.82).
At baseline, ten (45.4%) of the 20 boys converting to lipomastia 
in follow-up had a breast enlargement >4 cm on each side. At fol-
low-up, seven (31.2%) of these boys had a breast enlargement >4 cm 
on each side. At baseline, the breast diameters were 8 (median, IQR 
3–11, range 3–28) cm on the left size and 7 (median, IQR 3–11, range 
0–28) on the right size. At follow-up, the breast diameters were 4 
(median, IQR 2–9, range 1–32) cm on the left side and 4 (median, IQR 
1–11, range 0–32) cm on the right side. The changes of the breast 
diameter were on the left side −1 (median, IQR −6–1, range −8–8) 
cm and on the right side −1 (median, IQR −5–1, range −8–10) cm. 
The boys converting to lipomastia demonstrated an increase of their 
BMI-SDS during follow-up (+0.21, IQR 0.10–0.41, range −0.65–1.46).
3.1  |  Predictors of breast size regression
The associations between baseline parameters, changes in BMI-
SDS, duration of observation period, and changes in breast diameter 
are presented in Table 2. Except changes in BMI-SDS no other pa-
rameter was significantly related to changes in breast diameter (see 
also Figure 3). The 14 boys without an increase of their BMI-SDS 
during the follow-up period, reduced their breast diameter signifi-
cantly (left: −2 (median, IQR −6 to −1, range −8–1) cm, p = .003; right: 
−3 (median, IQR −6 to −3, range −8–0) cm, p = .002). The 17 boys, 
who increased their BMI-SDS during the follow-up period, demon-
strated no change of their breast diameter (left: 0 (median, IQR-2–5, 
range −8–10) cm, p = .362; right: 0 (median, IQR −2–5, range −8–10) 
cm, p = .346).
In multiple linear regression analysis the following independent 
variables were assessed: observation period, as well as age, BMI-SDS, 
E2, E3, FSH and E2/T ratio at first presentation. In contrast, the other 
parameters in Table 2 were excluded since their p-values in univariate 
regression was ≥0.10. The regression model, using backwards param-
eter selection, revealed that only the change in BMI-SDS (follow-up 
measurement minus baseline) was significantly related to the reduction 
in breast diameter. The regression coefficient for delta BMI-SDS was 
6.0 (95% confidence interval 1.3–10.7, p = .015). This model resulted 
in a r2 of .19, indicating that 19% of between-subject variability was 
explained by the change in BMI-SDS during the observation period.
3.2  |  Predictors of persistence of breast glandular 
tissue in ultrasound
The comparison between boys with persistence of breast glandu-
lar tissue and boys with complete disappearance of breast glandular 
tissue in ultrasound is presented in Table 3. None of the hormones 
analysed at the first presentation in our clinic differed significantly 
between the boys with persistence or disappearance of breast glan-
dular tissue in ultrasound.
4  |  DISCUSSION
This longitudinal study analysed the breast regression in pubertal 
boys with gynaecomastia differentiating between breast glandu-
lar tissue and adipose tissue using ultrasound. In line with the as-
sumption that gynaecomastia in pubertal boys is reversible in most 
cases,1,4-10 breast glandular tissue disappeared in the ultrasound 
examination in two thirds of our patients. However, a remarkable 
number of our patients converted from gynaecomastia to lipomastia 
at the follow-up examination.
Our findings of regression of breast diameters in boys with gy-
naecomastia but with a remaining breast swelling (which seems to 
be adipose tissue) is contrary to expert opinions stating that only 
10% of boys at the age of 17 years have persistent breast enlarge-
ment.1,5 However, all longitudinal studies are in line with our find-
ings: The three-year longitudinal study of Biro et al in 377 boys 
TA B L E  2  Associations (r) between baseline variables, changes in 
BMI-SDS, duration of breast swelling, and duration of observation 
period with changes in breast diameters in the observation period 










Breast diameter −.04 −.06
Testes volume right .03 .05
Testes volume left −.06 −.03












Duration of observation period .11 .14
Changes in BMI-SDS .54 .53
Note: Significant associations (p < .005) are plotted in bold, Spearman 
rank correlation.
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aged 10-15 years reported that approximately half of adolescent 
boys with gynaecomastia have persistent breast swelling. Mieritz 
et al reported in a nine-year longitudinal study that 19 (37%) of 
52 boys with gynaecomastia still had breast development at the 
end of the study.7 These two studies did not differentiate between 
lipomastia and gynaecomastia by ultrasound. Therefore, it is not 
F I G U R E  3  Changes of breast diameter related to changes in weight status as BMI-SDS during 2.4 years of follow-up (Spearman rank 
correlation) in 31 pubertal boys with gynaecomastia at initial presentation
TA B L E  3  Comparison of boys with and without disappearance of breast glandular tissue in ultrasound
Disappearance of breast glandular 





Age [years] 13.1 (11.7–14.1) [11.7–16.1] 13.9 (12.8–15.4) [11.8–16.1] .204
BMI-SDS 0.90 (0.20–1.68) [−1.15–2.96] 0.53 (0.06–2.03) [−0.94–2.50] .658
Duration of breast swelling before 
presentation [months]
6 (3–12) [2–30] 24 (12–30) [12–36] .011
Breast diameter left [cm] 8 (4–11) [3–28] 8 (5–11) [4–21] .774
Breast diameter right [cm] 7 (3–11) [0–28] 8 (4–12) [0–21] .768
Testis volume right [ml] 6 (5–9) [4–15] 10 (5–13) [4–20] .047
Testis volume left [ml] 6 (5–8) [4–15] 10 (5–14) [4–20] .045
Tanner stage P 2 (2–3) [1–5] 4 (3–5) [2–5] .005
LH [mU/ml] 2.1 (0.8–2.9) [0.1–3.5] 2.8 (2.3–3.5) [0.1–4.4] .182
FSH [mU/ml] 2.2 (1.3–3.4 [0.2–7.0] 2.8 (1.6–5.1) [0.5–7.1] .590
E1 [pM/L] 19 (11–49) [11–112] 25 (17–42) [11–109] .536
E2 [pM/L] 29 (11–48) [10–151] 61 (44–79) [28–123] .001
E3 [pM/L] 10 (10–13) [10–58] 10 (10–10) [10–49] .822
E2/T 28 (8–73) [2–138] 15 (7–64) [4–131] .567
DHT [nM/L] 0.2 (0.1–0.4) [0.1–4.1] 0.3 (0.1–0.4) [0.1–0.7] .352
A [nM/L] 1.0 (0.6–1.9) [0.2–46.7] 1.0 (0.8–1.5) [0.8–2.2] .368
T [nM/L] 1.0 (0.5–2.4) [0.2–5.6] 2.2 (1.3–7.6) [0.8–16.0] .013
IGF-1-SDS -0.4 (−1.1–0.3) [−1.6–1.4] -0.1 (−0.6–0.4) [−1.3–0.9] .500
IGFBP-3-SDS -0.2 (−0.7–0.4) [−1.29–1.3] -0.1 (−0.4–0.6) [−1.11–0.94] .385
At follow-up
Observation period [Years] 2.7 (1.4–3.4) [1.0–4.8] 1.9 (1.3–2.5) [1.3–4.6] .660
Change in BMI-SDS -0.09 (−0.47–0.45) [−1.76–1.46] 0.21 (0.01–0.40) [−0.65–0.82] .642
Note: Data as median, interquartile range in () and range in []; p-values derived from U-test (not normally distributed variables) or from unpaired t-test 
(normally distributed variables).
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ruled out that there was a transformation from gynaecomastia to 
lipomastia according to our study in those cases with persistent 
breast swelling. One might speculate that this transformation is 
the result of distension of the skin through breast tissue during 
the period of gynaecomastia which -when breast tissue disap-
peared- did not normalize completely. The feature in ultrasound 
at follow-up seems to represent at least in part the subcutaneous 
adipose tissue.
The only significant predictor for a decrease of breast swelling 
in our pubertal boys with gynaecomastia was the reduction in BMI-
SDS during the observation period, while all hormones at baseline 
were not related to breast regression in our study. Since many boys 
converted from gynaecomastia to lipomastia during follow-up and 
lipomastia is related to weight status3 it seems not surprising that 
changes of BMI-SDS were a predictor of breast regression. However, 
the likelihood that glandular tissue remained in our cohort was in-
dependent from change of BMI-SDS or any hormone determined 
at baseline. The lack of an impact of sex hormones on the breast 
regression or disappearance of breast glandular tissue in ultrasound 
in our study maybe explained with the hypothesis that hormonal 
changes (oestrogen/androgen imbalance) precede the enlargement 
of breast tissue and are not detectable at presentation.10 However, 
we have reported previously an E2/T imbalance in pubertal boys 
with gynaecomastia in contrast to pubertal boys with pseudogynae-
comastia or without breast enlargement.3
Apart from sex hormones a role of the growth hormone (GH) /
IGF-1 axis on the pathogenesis of gynaecomastia has been specu-
lated,7 since enlargement of mammary glands following exogenous 
GH administration has been observed.18,19 A significant positive 
association between breast enlargement and IGF-1 levels in puber-
tal boys has been reported in two studies from the same research 
group,7,9 while confirmatory studies are missing. In our study IGF-1 
concentrations at baseline were not a predictor of breast regression 
or disappearance of breast glandular tissue in ultrasound.
4.1  |  Strengths and limitations of the study
The strengths of this study are analysing a cohort of pubertal boys 
with manifestation of gynaecomastia at a typical age around 13 years 
of age,1,6,7,20,21 analyses of a comprehensive profile of sex hormones 
and their precursors by a state-of-the-art LC-MS/MS multisteroid 
profiling method12 and the differentiation between lipomastia and 
gynaecomastia by ultrasound. The latter is of importance since many 
other studies reported that boys with breast enlargement are fre-
quently obese.1,6,22 Our findings suggest that boys with lipomastia 
were likely included in most previous studies of adolescent gynaeco-
mastia making previous studies difficult to interpret.
However, our study presents some potential limitations. First, 
only one third of the initial study population agreed to participate 
in this follow-up examination probably leading to a selection bias. 
Therefore, we cannot exclude that the number of boys with com-
plete regression of their breast enlargement is higher than in our 
cohort. Therefore, we cannot give an exact number of boys with 
gynaecomastia who will convert to lipomastia. Assuming that all 
55 boys with gynaecomastia who did not agree to participate in 
this longitudinal study had a complete breast regression, the por-
tion of boys converting from gynaecomastia to lipomastia would 
still be 31%. Second, we cannot exclude the possibility that other 
androgens and oestrogens or sex hormone binding globulins not 
measured in this study might influence the development of physi-
ological gynaecomastia. For example, 11-ketotestosterone is very 
abundant in pubertal children and active at the androgen recep-
tor23,24 and the desulfation of E1 sulphate to E1 might play also a 
role.25 Third, we have not measured pubertal stages, sex hormones 
or IGF-1 during or at the end of the follow-up period. We decided to 
avoid blood drawing and to avoid displeasing examinations to have 
the highest number as possible of boys with available follow-up. 
Fourth, serum samples do not necessarily reflect the intra-tissue 
conditions in the breast. For example, subcutaneous skin seems to 
contribute significantly in the biosynthesis of steroidogenesis in-
cluding sex hormones.26 Fifth, the differentiation between adipose 
and breast glandular tissue has not been proven by histological bi-
opsies due to ethical reasons. Sixth, the follow-up period might be 
too short for detecting complete regression of the breast enlarge-
ment. However, previous longitudinal studies have reported that 
gynaecomastia lasts usually between <1-2 years.7,8 Therefore, our 
observation period of in mean > 2 years seems not to be too short. 
Furthermore, in the majority of the boys gynaecomastia was not 
detectable in ultrasound even when a (smaller) breast enlargement 
exists. The finding of remarkable adipose tissue in ultrasound at fol-
low-up points against a complete regression of breast enlargement 
in longer follow-up. Seventh, our multiple linear regression model 
explains only 19% of variance of the breast regression suggesting 
further important contributors. Finally, due to the moderate study 
sample our study is rather hypothesis generating and does not allow 
final conclusions.
In summary, we were not able to identify in pubertal boys with 
gynaecomastia a special hormone profile predicting breast regres-
sion or disappearance of breast glandular tissue in ultrasound. We 
found a remarkable portion of boys converting from gynaecomas-
tia to lipomastia at the follow-up examination. An important factor 
for the regression of breast enlargement seems to be the change of 
weight status in pubertal boys. Therefore, boys with gynaecomastia 
should be advised not to increase their weight status to avoid lipo-
mastia. Future larger longitudinal studies with lower drop-out rates 
are necessary to estimate the number of pubertal boys with gynae-
comastia converting to lipomastia and to confirm our observation 
that change of weight status is related to breast regression.
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